175358-01-7

Basic information

• Product Name: 6-Chloro-3-aminopyridine-2-carboxamide
• Synonyms: 6-Chloro-3-aminopyridine-2-carboxamide;3-amino-6-chloropicolinamide;3-aMino-6-chloropyridine-2-carboxaMide;3-AMino-6-chloro-pyridine-2-carboxylic acid aMide
• CAS NO: 175358-01-7
• Molecular Formula: C₆H₆ClN₃O
• Molecular Weight: 171.59
• EINECS: 1312995-182-4
• Product Categories: Pyridines
• Mol File: 175358-01-7.mol

Chemical Properties

• Boiling Point: 349.303 °C at 760 mmHg
• Flash Point: 165.053 °C
• Appearance: /
• Density: 1.484 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.655
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 14.26±0.50(Predicted)
• CAS DataBase Reference: 6-Chloro-3-aminopyridine-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Chloro-3-aminopyridine-2-carboxamide(175358-01-7)
• EPA Substance Registry System: 6-Chloro-3-aminopyridine-2-carboxamide(175358-01-7)

Safety Data

• Hazardous Substances Data: 175358-01-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Chloro-3-aminopyridine-2-carboxamide is used as an intermediate in the synthesis of various pharmaceuticals and agrochemicals. Its unique structure and functional groups contribute to the development of new drugs with improved therapeutic effects.
Used in Organic Material Production:
6-Chloro-3-aminopyridine-2-carboxamide is used in the production of organic materials, where its chemical properties allow for the creation of novel compounds with specific characteristics, enhancing the performance of these materials in various applications.
Used in Research and Drug Development:
6-Chloro-3-aminopyridine-2-carboxamide is commonly utilized in research and drug development due to its versatile reactivity and potential pharmacological properties. It serves as a building block for the development of potentially bioactive molecules, contributing to the discovery of new therapeutic agents and advancing the field of medicinal chemistry.

InChI:InChI=1/C6H6ClN3O/c7-4-2-1-3(8)5(10-4)6(9)11/h1-2H,8H2,(H2,9,11)

Upstream product

• 171178-21-5 6-chloro-3-nitropyridine-2-carboxamide 
• 93683-65-9 6-chloro-3-nitropicolinonitrile 
• 16013-85-7 2,6-dicholoro-3-nitropyridine 
• 95095-84-4 3-amino-6-chloro-pyridine-2-carbonitrile 
• 2402-78-0 2,6-dichloropyridine 

Downstream Products

• 171178-33-9 6-chloropyrido<3,2-d>pyrimidin-4(3H)-one 
• 897359-74-9 2-amino-6-chloropyrido[3,2-d]pyrimidin-4(3H)-one 
• 897360-38-2 6-chloropyrido[3,2-d]pyrimidine-2,4(1H,3H)-dione 
• 1367359-31-6 C₂₉H₃₂N₄O₂ 
• 1367359-24-7 6-(4-fluorophenoxy)-3-((S)-1-isopropylpiperidin-3-ylmethyl)-2-methyl-3H-pyrido[3,2-d]pyrimidin-4-one 
• 1367359-25-8 6-(4-chloro-2-fluorophenoxy)-3-((S)-1-isopropylpiperidin-3-ylmethyl)-2-methyl-3H-pyrido[3,2-d]pyrimidin-4-one 
• 1367359-28-1 (S)-6-(4-bromo-2-fluorophenoxy)-3-((1-isopropylpiperidin-3-yl)methyl)-2-methylpyrido[3,2-d]pyrimidin-4(3H)-one 
• 1400668-23-6 6-chloro-N-(4-(trifluoromethoxy)phenyl)pyrido[3,2-d]pyrimidin-4-amine 
• 1112213-20-3 3-amino-6-chloro-picolinic acid hydrochloride 
• 175358-02-8 4,6-dichloropyrido<3,2-d>pyrimidine 
• 866807-27-4 3-amino-6-chloro-pyridine-2-carboxylic acid 
• 917758-83-9 3-amino-6-(4-fluorophenyl)pyridine-2-carboxamide 
• 1203653-35-3 (R)-N₂-(1-(4-(1H-1,2,4-triazol-1-yl)phenyl)ethyl)-6-(4-methoxy-3-(methylsulfonyl)phenyl)-N₄-(2,2,2-trifluoroethyl)pyrido[3,2-d]pyrimidine-2,4-diamine 

Relevant articles and documents

Fragment-based drug discovery of potent and selective MKK3/6 inhibitors

The MAPK signaling cascade, comprised of several linear and intersecting pathways, propagates signaling into the nucleus resulting in cytokine and chemokine release. The Map Kinase Kinase isoforms 3 and 6 (MKK3 and MKK6) are responsible for the phosphorylation and activation of p38, and are hypothesized to play a key role in regulating this pathway without the redundancy seen in downstream effectors. Using FBDD, we have discovered efficient and selective inhibitors of MKK3 and MKK6 that can serve as tool molecules to help further understand the role of these kinases in MAPK signaling, and the potential impact of inhibiting kinases upstream of p38.

Optimization of 4,6-Disubstituted Pyrido[3,2-d]pyrimidines as Dual MNK/PIM Inhibitors to Inhibit Leukemia Cell Growth

Mitogen-activated protein kinase-interacting kinases (MNKs) and provirus integration in maloney murine leukemia virus kinases (PIMs) are downstream enzymes of cell proliferation signaling pathways associated with the resistance of tyrosine kinase inhibitors. MNKs and PIMs have complementary effects to regulate cap-dependent translation of oncoproteins. Dual inhibitors of MNKs and PIMs have not been developed. We developed a novel 4,6-disubstituted pyrido[3,2-d]pyrimidine compound 21o with selective inhibition of MNKs and PIMs. The IC50’s of 21o to inhibit MNK1 and MNK2 are 1 and 7 nM and those to inhibit PIM1, PIM2, and PIM3 are 43, 232, and 774 nM, respectively. 21o inhibits the growth of myeloid leukemia K562 and MOLM-13 cells with GI50’s of 2.1 and 1.2 μM, respectively. 21o decreases the levels ofp-eIF4E andp-4EBP1, the downstream products of MNKs and PIMs, as well as cap-dependent proteins c-myc, cyclin D1, and Mcl-1. 21o inhibits the growth of MOLM-13 cell xenografts without causing evident toxicity. 21o represents an innovative dual MNK/PIM inhibitor with a good pharmacokinetic profile.

NITROGEN HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present disclosure relates to compounds of formula (I): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds as inhibitors of receptor tyrosine kinases, in particular oncogenic mutants of ErbB-receptors e.g. in the treatment of cancer.

SMALL MOLECULE INHIBITORS OF ACETYL COENZYME A SYNTHETASE SHORT CHAIN 2 (ACSS2)

The present invention relates to compounds of formula (I). The compounds may be used to modulate the acetyl coenzyme A synthetase short chain 2 (ACSS2) protein and may thereby treat, ameliorate or prevent a disease selected from cancer, bacterial infection, viral infection, parasitic infection, fungal infection, neurodegenerative disease, neurological disorder, cerebrovascular disease, cardiovascular disease, non- alcoholic fatty liver disease and obesity. Alternatively, or additionally, the compounds maybe used to promote healthy ageing.

4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound as well as preparation and application thereof

The invention belongs to the technical field of medicines. The invention relates to the field of pharmaceutical chemistry, in particular to a 4, 6-disubstituted pyridine [3, 2-d] pyrimidine compound and pharmaceutically acceptable salt thereof, a preparation method of the compound, a pharmaceutical composition taking the compound as an active ingredient, and application of the compound in preparation of an MNK inhibitor and drugs for treating and/or preventing various cancers and/or metabolic diseases. The present invention relates to compounds represented by formulas I, II, III or IV, and pharmaceutically acceptable salts, hydrates, solvates and metabolites thereof, wherein the variables are described in the claims and the description.

Design, synthesis and bioactivity evaluation of 4,6-disubstituted pyrido[3,2-d]pyrimidine derivatives as mnk and HDAC inhibitors

Both HDACs and Mnks play important role in translating multiple oncogenic signaling pathways during oncogenesis. As HDAC and Mnk are highly expressed in a variety of tumors; thus simultaneous inhibit HDAC and Mnk can increase the inhibition of tumor cell proliferation and provide a new way of inhibiting tumor growth. Based on the previous work and the merge pharmacophore method; we designed and synthesized a series of 4,6-disubstituted pyrido[3,2-d]pyrimidine derivatives as HDAC and Mnk dual inhibitors. Among them; compound A12 displayed good HDAC and Mnk inhibitory activity. In vitro antiproliferative assay; compound A12 exhibited the best antiproliferative activity against human prostate cancer PC-3 cells. Docking study revealed that the pyrido[3,2-d]pyrimidine framework and hydroxamic acid motif of compound A12 were essential for maintaining the activity of HDAC and Mnk. These result indicated that A12 was a potent Mnk /HDAC inhibitor and will be further researched.

2-METHYL-AZA-QUINAZOLINES

The present invention covers 2-methyl-aza-quinazoline compounds of general formula (I) as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients

Preparation method of novel substituted pyridine pyrimidine compound

The invention belongs to the field of pharmaceutical and chemical industry, and provides a preparation method of a novel substituted pyridine pyrimidine compound. The pyridine pyrimidine compound is of great significance to medical research and new drug development. The problem that an amide compound is easily destroyed by strong alkalis in a synthesis process under a high temperature condition issolved, and meanwhile the problem that a pyrimidine 4-amino group is difficult to react to synthesize amide due to poorer amino activity is solved. Moreover, a two-step reaction for reducing a nitrogroup into an amino group and hydrolyzing cyano group into the amide group is completed in a one-step reaction, thereby simplifying the reaction flow. The invention provides a preparation method of the compound. The compound provides important support for the application of the compound in the field of new drug development in the future in terms of synthesis conditions, methods and processes.

QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS

The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8' are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment/ the disease is cancer.

NEW CHEMICAL COMPOUNDS

The present invention encompasses compounds of general formula (1) wherein the groups R1 to R4, Qa, Qb, QH, L and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, pharmaceutical preparations which contain such compounds and their use as medicaments.